The effect of protease inhibitors on the cervical mucus of HIV-positive women taking norethindrone contraception

Jessica M. Atrio, Alice Stek, Hita Vora, Lorraine Sanchez-Keeland, Ferdous Zannat, Melissa Natavio

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To compare cervical mucus score (CMS) with and without protease inhibitors (PI) before and after taking norethindrone (NET). Study design: This two-arm, researcher blinded, non-randomised, prospective study was conducted to evaluate cervical mucus quality in HIV-positive women taking progestin only pills. The study group was taking a PI, and compared to women taking ARV regimens that have demonstrated no significant interaction with NET in prior pharmacokinetic trials with combined oral contraceptives. The women had a cervical mucus score prior to NET administration. Mucus Scoring was repeated after 21 days of steady state exposure to oral NET 0.35 milligrams. Cervical mucus quality was quantified according to the World Health Organisation criteria, which include: volume, consistency, cellularity, spinnbarkeit, and ferning. Results: Sixteen women took PI and 17 were controls. Baseline CMS were similar (p ≥ 0.1). After 21 days CMS were similar among the two groups (p = 1). Conclusions: HIV-positive women taking PI demonstrated thickened cervical mucus with oral norethindrone 0.35 mg and are similar to HIV-positive women taking no PI therapy. This may suggest no difference in contraceptive efficacy of progestin only pills in HIV-positive women taking PI.

Original languageEnglish (US)
Pages (from-to)149-153
Number of pages5
JournalEuropean Journal of Contraception and Reproductive Health Care
Volume20
Issue number2
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Cervix Mucus
Norethindrone
Protease Inhibitors
Contraception
HIV
Progestins
Contraceptives, Oral, Combined
Mucus
Contraceptive Agents
Pharmacokinetics
Research Personnel
Prospective Studies

Keywords

  • AIDS
  • antiretroviral medication
  • contraceptive efficacy
  • drug interaction
  • hormonal contraception
  • progestin only pills

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pharmacology (medical)
  • Reproductive Medicine

Cite this

The effect of protease inhibitors on the cervical mucus of HIV-positive women taking norethindrone contraception. / Atrio, Jessica M.; Stek, Alice; Vora, Hita; Sanchez-Keeland, Lorraine; Zannat, Ferdous; Natavio, Melissa.

In: European Journal of Contraception and Reproductive Health Care, Vol. 20, No. 2, 01.04.2015, p. 149-153.

Research output: Contribution to journalArticle

Atrio, Jessica M. ; Stek, Alice ; Vora, Hita ; Sanchez-Keeland, Lorraine ; Zannat, Ferdous ; Natavio, Melissa. / The effect of protease inhibitors on the cervical mucus of HIV-positive women taking norethindrone contraception. In: European Journal of Contraception and Reproductive Health Care. 2015 ; Vol. 20, No. 2. pp. 149-153.
@article{063bb574de2b456f9844a3768244e2e1,
title = "The effect of protease inhibitors on the cervical mucus of HIV-positive women taking norethindrone contraception",
abstract = "Objective: To compare cervical mucus score (CMS) with and without protease inhibitors (PI) before and after taking norethindrone (NET). Study design: This two-arm, researcher blinded, non-randomised, prospective study was conducted to evaluate cervical mucus quality in HIV-positive women taking progestin only pills. The study group was taking a PI, and compared to women taking ARV regimens that have demonstrated no significant interaction with NET in prior pharmacokinetic trials with combined oral contraceptives. The women had a cervical mucus score prior to NET administration. Mucus Scoring was repeated after 21 days of steady state exposure to oral NET 0.35 milligrams. Cervical mucus quality was quantified according to the World Health Organisation criteria, which include: volume, consistency, cellularity, spinnbarkeit, and ferning. Results: Sixteen women took PI and 17 were controls. Baseline CMS were similar (p ≥ 0.1). After 21 days CMS were similar among the two groups (p = 1). Conclusions: HIV-positive women taking PI demonstrated thickened cervical mucus with oral norethindrone 0.35 mg and are similar to HIV-positive women taking no PI therapy. This may suggest no difference in contraceptive efficacy of progestin only pills in HIV-positive women taking PI.",
keywords = "AIDS, antiretroviral medication, contraceptive efficacy, drug interaction, hormonal contraception, progestin only pills",
author = "Atrio, {Jessica M.} and Alice Stek and Hita Vora and Lorraine Sanchez-Keeland and Ferdous Zannat and Melissa Natavio",
year = "2015",
month = "4",
day = "1",
doi = "10.3109/13625187.2014.957826",
language = "English (US)",
volume = "20",
pages = "149--153",
journal = "European Journal of Contraception and Reproductive Health Care",
issn = "1362-5187",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - The effect of protease inhibitors on the cervical mucus of HIV-positive women taking norethindrone contraception

AU - Atrio, Jessica M.

AU - Stek, Alice

AU - Vora, Hita

AU - Sanchez-Keeland, Lorraine

AU - Zannat, Ferdous

AU - Natavio, Melissa

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Objective: To compare cervical mucus score (CMS) with and without protease inhibitors (PI) before and after taking norethindrone (NET). Study design: This two-arm, researcher blinded, non-randomised, prospective study was conducted to evaluate cervical mucus quality in HIV-positive women taking progestin only pills. The study group was taking a PI, and compared to women taking ARV regimens that have demonstrated no significant interaction with NET in prior pharmacokinetic trials with combined oral contraceptives. The women had a cervical mucus score prior to NET administration. Mucus Scoring was repeated after 21 days of steady state exposure to oral NET 0.35 milligrams. Cervical mucus quality was quantified according to the World Health Organisation criteria, which include: volume, consistency, cellularity, spinnbarkeit, and ferning. Results: Sixteen women took PI and 17 were controls. Baseline CMS were similar (p ≥ 0.1). After 21 days CMS were similar among the two groups (p = 1). Conclusions: HIV-positive women taking PI demonstrated thickened cervical mucus with oral norethindrone 0.35 mg and are similar to HIV-positive women taking no PI therapy. This may suggest no difference in contraceptive efficacy of progestin only pills in HIV-positive women taking PI.

AB - Objective: To compare cervical mucus score (CMS) with and without protease inhibitors (PI) before and after taking norethindrone (NET). Study design: This two-arm, researcher blinded, non-randomised, prospective study was conducted to evaluate cervical mucus quality in HIV-positive women taking progestin only pills. The study group was taking a PI, and compared to women taking ARV regimens that have demonstrated no significant interaction with NET in prior pharmacokinetic trials with combined oral contraceptives. The women had a cervical mucus score prior to NET administration. Mucus Scoring was repeated after 21 days of steady state exposure to oral NET 0.35 milligrams. Cervical mucus quality was quantified according to the World Health Organisation criteria, which include: volume, consistency, cellularity, spinnbarkeit, and ferning. Results: Sixteen women took PI and 17 were controls. Baseline CMS were similar (p ≥ 0.1). After 21 days CMS were similar among the two groups (p = 1). Conclusions: HIV-positive women taking PI demonstrated thickened cervical mucus with oral norethindrone 0.35 mg and are similar to HIV-positive women taking no PI therapy. This may suggest no difference in contraceptive efficacy of progestin only pills in HIV-positive women taking PI.

KW - AIDS

KW - antiretroviral medication

KW - contraceptive efficacy

KW - drug interaction

KW - hormonal contraception

KW - progestin only pills

UR - http://www.scopus.com/inward/record.url?scp=84924956640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924956640&partnerID=8YFLogxK

U2 - 10.3109/13625187.2014.957826

DO - 10.3109/13625187.2014.957826

M3 - Article

C2 - 25285572

AN - SCOPUS:84924956640

VL - 20

SP - 149

EP - 153

JO - European Journal of Contraception and Reproductive Health Care

JF - European Journal of Contraception and Reproductive Health Care

SN - 1362-5187

IS - 2

ER -